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Hepatic periportal fibrosis (PPF), associated with portal hypertension, is a major pathological consequence
of infections with Schistosoma mansoni and Schistosoma japonicum. Indeed, affected subjects may die from
portal hypertension. Previous studies have indicated that tumor necrosis factor alpha (TNF-) may aggravate
fibrosis. We therefore investigated whether PPF was associated with certain polymorphisms of the TNF- gene.
Four polymorphisms (TNF- 376 G/A, 308 G/A, 238 G/A, and 488 G/A) were investigated in two
Sudanese populations living in an area in which S. mansoni is endemic. These polymorphisms were analyzed
for 105 Sudanese subjects with various grades of PPF, from mild to advanced; all subjects were from two
neighboring villages (Taweela and Umzukra). They were then analyzed for 70 subjects with advanced liver
disease and for 345 matched controls from the Gezira region. We found no evidence of associations between
these four polymorphisms and PPF in both of these studies. Thus, these four polymorphisms, two of which
(TNF- 376 and 308) were found to increase TNF- gene transcription, are unlikely to have a major effect
on PPF progression in these populations. However, this result does not exclude the possibility that these
polymorphisms have a minor effect on PPF development.
Schistosomiasis is a serious public health problem affecting
over 200 million people in developing countries (15, 41). Most
of the infections occurring in areas where schistosomes are
endemic are asymptomatic. However, 5 to 15% of infected
individuals develop severe disease with Symmers fibrosis.
Schistosomes (Schistosoma mansoni) produce several hundred
eggs per day, and a proportion of these eggs are trapped in
hepatic tissues and in presinusoidal venules. There, they in-
duce a granulomatous inflammation that leads, in certain sub-
jects, to the accumulation of scar tissue in the periportal
spaces. Periportal fibrosis (PPF) causes venous obstruction and
portal blood hypertension and contributes to the development
of splenomegaly. Severely affected patients develop esopha-
geal varices, ascites, and cachexia, resulting in death in the
absence of treatment. Fibrosis, which involves stellate (Ito)
cells derived from fibroblasts, results from an imbalance be-
tween the positive and negative regulatory mechanisms con-
trolling the production and degradation of extracellular matrix
proteins (ECMP). The production of collagen and ECMP is
stimulated by a variety of cytokines and growth factors (inter-
leukin-1 [IL-1], IL-4, IL-13, tumor necrosis factor alpha [TNF-
]), monocyte chemotactic protein 1, platelet-derived growth
factors, and transforming growth factor ), which stimulate
fibroblast differentiation and the production of ECMP by fi-
broblasts, Kupffer cells, and endothelial cells (14, 16, 22, 30).
Other cytokines, such as alpha interferon (IFN-) and IFN-,
have the opposite effect (6). ECMP turnover depends on ma-
trix metalloproteases and their inhibitors, the tissue inhibitors
of metalloproteases, the synthesis of which is also regulated by
various cytokines, including TNF-, transforming growth fac-
tor , and IFN- (33, 34).
We have studied the development of PPF in a Sudanese
population from the village of Taweela, which is located in a
region where S. mansoni is endemic (36). We have shown that
advanced PPF associated with portal hypertension is under the
control of a major genetic locus (SM2) that is closely linked to
IFNGR1, the gene encoding the alpha chain of the IFN-
receptor (18). Analysis of the production of cytokines by the
mononuclear cells present in the blood of these subjects
showed that high IFN- levels were associated with a much
lower risk of PPF and that high TNF- levels were associated
with a high risk of PPF (25). These findings are consistent with
the known antifibrogenic properties of IFN- (see reference 26
for a review). TNF- has been reported to modulate the gran-
ulomatous reaction induced by schistosome eggs (5, 29). Sev-
eral reports have also suggested that TNF- may increase
hepatic fibrosis and severe disease in S. mansoni infections: in
chronically infected CBA/J mice, TNF- mRNA levels in-
crease with the collagen content of the liver and with spleno-
megaly (3), and similar results have been obtained in BALB/c
mice infected with S. mansoni (32). Furthermore, TNF- in-
creases superoxide production and downregulates the chemo-
tactic response of human neutrophils, thereby probably in-
creasing inflammation (7, 42). Finally, in diseases caused by
parasites, such as cerebral malaria and cutaneous leishmania-
sis, in which there is an exaggerated inflammatory reaction to
parasite antigens, aggravation of the clinical status of the pa-
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tient has been shown to be associated with polymorphisms that
increase the levels of transcription of the TNF- and TNF-
genes (11, 26, 31, 35, 46). We therefore investigated whether
progression to severe PPF in schistosomiasis was associated
with polymorphisms in the TNF- gene. We began by investi-
gating the possible association of PPF with polymorphisms in
the TNF- promoter (376 G/A, 308 G/A, and 238 G/A)
and in exon 1 (488 G/A) in residents of the Sudanese villages
of Taweela and Umzukra in the Gezira region and in another
cohort selected from the same region, in which S. mansoni is
endemic.
MATERIALS AND METHODS
Blood samples. Ten to 15 milliliters of venous blood was collected on Na
citrate. Genomic DNA was prepared by a classical standard salting-out method.
PCR amplification. Four different mutations were screened for samples from
the village population and the case-control cohort. Oligonucleotides were ob-
tained from MWG Biotech, Courtaboeuf, France, and restriction enzymes were
purchased from Life Technologies, Cergy-Pontoise, France. TNF gene se-
quences from all individuals included in this study were amplified by PCR. The
reaction mixtures (30 l) contained 100 ng of genomic DNA, a 1 mM concen-
tration of each primer, a 0.25 mM concentration of each nucleotide, 1.5 mM
MgCl2, and 1.5 U of Taq polymerase in 1 commercial buffer (Appligene,
Illkirch, France). The temperature cycles were 1 min at 94°C for denaturation,
45 s at the specific annealing temperature of each primer, and 45 s at 72°C for
elongation for 35 cycles in Stratagene Robocycler 96. Amplified products were
visualized on a 1.5 or 2% agarose gel with ethidium bromide (1 mg/ml) staining.
Primer sequences and analysis of TNF allele frequency. The TNF- 238
(G/A) polymorphism in the promoter of the TNF- gene was determined by
PCR amplification (17) with the primers 238F (5 GGT CCT ACA CAC AAA
TCA GT 3) and 238R (5 CAC TCC CCA TCC TCC CTG GTC 3). At the 3
end of the reverse primer, C has been changed to G (underlined base) in order
to facilitate detection of the mutation by restriction enzyme digestion. The 71-bp
fragment generated by PCR was digested with the AvaII enzyme under the
conditions described by the manufacturer. Digestion products were analyzed on
a 12% acrylamide gel (37.5:1) stained with ethidium bromide (1 mg/ml). The
PCR products from patients who were homozygous for allele 238A (238A/A)
gave a single 71-bp fragment after digestion, whereas those from patients who
were homozygous for allele 238G (238 G/G) were completely digested (51-
and 20-bp fragments). Three fragments of 71, 51, and 20 bp were present in the
patients who were heterozygous.
The TNF- 308 (G/A) polymorphism in the promoter of the TNF- gene
was determined by PCR amplification with the primers 308F (5 AGG CAA
TAG GTT TTG AGG GCC AT 3) and 308R (5 TCC TCC CTG CTC CGA
TTC CG 3) (47). A single base change at the 3 end of the forward primer
(underlined) was required for the formation of a NcoI recognition sequence. The
107-bp fragment was digested with the NcoI enzyme, and digestion products
were analyzed on 10% acrylamide gel (37.5:1) stained with ethidium bromide
solution (1 mg/ml). The PCR products from patients who were homozygous for
allele 308A (308 A/A) gave a single 107-bp fragment, whereas those from
patients who were homozygous for allele 308G (308 G/G) were completely
digested (87- and 20-bp fragments).
The TNF- 376 (G/A) polymorphism in the promoter of the TNF- gene
was previously determined by PCR amplification (24) with the primers 376F
(5 CCC CGT TTT CTC TCC CTC AA 3) and 376R (5 TGT GGT CTG TTT
CCT TCT AA 3). The 106-bp PCR fragment was digested with the Tsp509I
enzyme. Digestion products were analyzed on a 10% acrylamide gel (37.5:1)
stained with ethidium bromide solution (1 mg/ml). The PCR products from
homozygotes for allele 376G (376 G/G) were not digested and gave a single
106-bp fragment, whereas in homozygotes for allele 376A (376 A/A) frag-
ments were completely digested (86 and 20 bp).
The TNF- 488 (G/A) polymorphism in intron 1 of the TNF- gene was
associated with granulomatous common variable immunodeficiency (20, 37).
PCR amplifications were performed with the primers 488F (5 CAG AGG
GAA GAG GTG AGT GC 3) and 488R (5 GCC AGA CAT CCT GTC TCT
CC 3). A 220-bp PCR fragment was digested with the NlaIII enzyme. Digestion
products were analyzed on a 10% acrylamide gel (37.5:1) stained with ethidium
bromide solution (1 mg/ml). The PCR products from homozygotes for allele
488G (488 G/G) were not digested and gave a single 220-bp fragment,
whereas in homozygotes for allele 488A (488 A/A) fragments were com-
pletely digested (82 and 138 bp).
Statistical analysis. Fisher’s exact test and the chi-square test were performed
with SPSS software.
RESULTS AND DISCUSSION
The first part of the study concerned the populations of two
villages (Taweela and Umzukra) in the Gezira region of Sudan
(Table 1). PPF was studied by ultrasound, making it possible to
grade the disease (F0, FI, FII, and FIII), as described else-
where (12). The study population consisted of 105 subjects: 56
had no fibrosis (F0) or mild fibrosis (FI), and 49 individuals
TABLE 1. Distribution of TNF- polymorphisms in the populations of Taweela and Umzukraa
Polymorphism Genotype
No. with genotype/no. genotyped (% with genotype) in:
Whole population
Clinical group:
F0 FI FII FIII
TNF- 376 G/G 96/98 (97.96) 30/30 (100) 23/23 (100) 18/18 (100) 25/27 (92.59)
G/A 2/98 (2.04) 0/30 (0) 0/23 (0) 0/18 (0) 2/27 (7.41)
A/A 0/98 (0) 0/30 (0) 0/23 (0) 0/18 (0) 0/27 (0)
TNF- 308 G/G 81/97 (83.5) 23/30 (76.67) 21/23 (91.3) 16/17 (94.12) 21/27 (77.78)
G/A 14/97 (14.43) 5/30 (16.67) 2/23 (8.7) 1/17 (5.88) 6/27 (22.22)
A/A 2/97 (2.06) 2/30 (6.66) 0/22 (0) 0/17 (0) 0/27 (0)
TNF- 238 G/G 89/99 (89.9) 30/31 (96.8) 20/24 (83.3) 16/17 (94.1) 23/27 (85.2)
G/A 8/99 (8.08) 1/31 (3.2) 3/24 (12.5) 1/17 (5.9) 3/27 (11.1)
A/A 2/99 (2.02) 0/31 (0) 1/24 (4.2) 0/17 (0) 1/27 (3.7)
TNF- 488 G/G 80/97 (82.47) 25/30 (83.3) 22/24 (91.7) 14/19 (73.7) 19/24 (79.2)
G/A 16/97 (16.5) 5/30 (16.7) 2/24 (8.3) 4/19 (21.0) 5/24 (10.8)
A/A 1/97 (1.03) 0/30 (0) 0/24 (0) 1/19 (5.3) 0/24 (0)
a PPF was evaluated by ultrasound scan (portable Aloka SSD 500 Echo camera and 3.5-MHz convex probe) for all of the residents of Taweela (n 	 770) and for
one-third of the population of Umzukra (n 	 700). Family relationships were determined for the populations of both villages. For the study group, we included all
unrelated subjects from these two villages. If several choices of individual were possible, we systematically selected the oldest subject because PPF develops mainly in
individuals over 20 years old in this population (17). Based on these criteria, we selected 105 unrelated individuals from those who volunteered to give blood samples.
TNF- genotypes were determined as previously described (16, 19, 24, 38, 48).
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displayed advanced fibrosis (FII or FIII), which was associated
with portal hypertension in a third of the FII subjects and in all
FIII subjects. These individuals were genotyped for the TNF-
(376, 308, 208, and 488) polymorphisms. The frequen-
cies of these polymorphisms in each clinical group are indi-
cated in Table 1. Statistical analysis of the frequencies of the
various phenotypes in F0, FI, and FII subjects showed that
these polymorphisms were in Hardy-Weinberg equilibrium
(Table 2) (
2  5.99).
We then increased the sizes of the groups to be compared by
assigning study subjects to one of two groups: one group was
composed of the F0, FI, and FII subjects, and the other con-
sisted of the subjects with the most severe fibrosis (FIII). No
statistically significant difference in genotype distribution be-
tween these two clinical groups was observed in studies of
the TNF- 238, 308, and 488 polymorphisms. However,
there was a trend for an association of TNF- 376A and FIII
(P 	 0.074, not taking into account multiple comparison) (Ta-
ble 2). The frequency of the TNF- 376 G/A genotype was
higher (7.4 versus 0%) in FIII subjects than in subjects with less
severe fibrosis. This polymorphism may increase the level of
transcription of the TNF- gene (31). As some FII subjects
may progress to FIII, we repeated the analysis, comparing FIII
with F0 and FI subjects. This additional analysis showed that
there was no statistically significant association between any of
the TNF- polymorphisms tested and either of the two clinical
groups (not shown).
The second part of the study was carried out with subjects
recruited at the endoscopy unit of Wad Medani Teaching Hos-
pital and with controls recruited from contributors to the Wad
Medani blood bank or from nearby villages (Table 3). Seventy
patients with PPF and portal hypertension and 345 unrelated
matched controls were included in this part of the study. Ge-
notype frequencies (TNF- 376, 308, and 238 polymor-
phisms) are indicated in Table 3. None of these polymorphisms
displayed significant deviation from Hardy-Weinberg equilib-
rium in the control group (Table 3) (
2  5.99). We used the
chi-square test to assess the association between PPF and poly-
morphisms in TNF- promoter region (308, 376, and
238). None of these polymorphisms, including TNF- 376,
was associated with severe disease (Table 3) (P  0.5).
In the Taweela population, PPF has been shown to be as-
sociated with an increase in TNF- production (25). Other
studies have also indicated that advanced hepatic disease is
more likely to occur in human schistosomiasis patients with
higher levels of TNF- production (38, 48). Studies in vitro and
with experimental models have shown that TNF- is required
for granuloma formation and the development of hepatic fi-
brosis (9, 13, 19, 32). Nevertheless, the role of TNF- in the
aggravation of fibrosis remains unclear, because TNF- may
protect against PPF (4, 27) or aggravate this condition (5, 8, 39,
45) in schistosomiasis. TNF- protects IL-12-vaccinated mice
against the deleterious effects of the granuloma (27) and in-
creases the production of NO, the hypotensive effects of which
may be beneficial in patients with portal hypertension (4).
However, TNF- also increases ECMP production by Kupffer
cells (21), stimulates matrix metalloprotease gene expression
(40), and may exacerbate hepatic inflammation by stimulating
the production of reactive oxygen species (39).
PPF and advanced liver disease are more severe in Egyp-
tians infected with S. mansoni who carry certain HLA haplo-
types. This indicates that HLA alleles or TNF- and TNF-
alleles in linkage disequilibrium with HLA haplotypes may
affect disease development (1, 2, 10, 43, 44). Polymorphisms at
the HLA locus and hepatosplenomegaly (HS) have also been
observed in schistosome-infected patients (1, 10, 43). However,
HS is not identical to the clinical phenotypes studied here,
because PPF may occur in the absence of HS and HS may
develop in the absence of advanced PPF (23, 25, 28). Two of
the alleles studied, TNF- 376A and 308A, increase tran-
scription of the TNF- gene (3, 31). The lack of a significant
TABLE 2. TNF- genotype distribution and genotype
frequencies in clinical groupsa
Poly-
morphism Genotype
No. with genotype/no.
genotyped (% with genotype)
in clinical group(s):
P (Fisher’s
exact test)b
F0, FI, and FIIa FIII
TNF- 376 G/G 71/71 (100) 25/27 (92.6) 0.074
G/A or A/A 0/71 (0) 2/27 (7.4) 1
TNF- 308 G/G 60/70 (85.7) 21/27 (77.8) 1
G/A or A/A 10/70 (14.3) 6/27 (22.2)
TNF- 238 G/G 66/72 (91.7) 23/27 (85.2) 1
G/A or A/A 6/72 (8.3) 4/27 (14.8)
TNF- 488 G/G 61/73 (83.6) 19/24 (79.2)
G/A or A/A 12/73 (16.4) 5/24 (20.8) 1
a The genotype distributions for the four polymorphisms did not deviate from
Hardy-Weinberg equilibrium within the F0-FI-FII group (
2 	 0, 5.07, 4.50, and
0.37 for TNF- 376, 308, 238, and 488, respectively).
b Fisher’s exact test was carried out with SPSS software to compare the two
study groups (F0-FI-FII versus FIII).
TABLE 3. TNF- genotype distribution and genotype
frequencies in the Gezira cohorta
Poly-
morphism
Geno-
type
No. with genotype/no. genotyped
(% with genotype) P (Fisher’s
exact test)c
Controlsb Cases
TNF- 376 G/G 321/344 (93.3) 66/70 (94.3)
G/A 22/344 (6.4) 3/70 (4.3) 1
A/A 1/344 (0.3) 1/70 (1.4)
TNF- 308 G/G 275/342 (80.4) 58/70 (82.9)
G/A 63/342 (18.4) 12/70 (7.1) 0.636
A/A 4/342 (1.2) 0/70 (0)
TNF- 238 G/G 288/341 (84.5) 58/70 (82.9)
G/A 52/341 (15.2) 11/70 (15.7) 0.738
A/A 1/341 (0.3) 1/70 (1.4)
a A case-control study was performed with patients recruited at the endoscopy
unit of Wad Medani Teaching Hospital (Sudan). Healthy controls were recruited
from contributors to the Wad Medani blood bank or from nearby villages. All
patients with evidence of PPF and varices attending the hospital during the study
period were included. Thus, the inclusion criteria were PPF diagnosed by ultra-
sound and esophageal varices diagnosed by endoscopy. The patients gave in-
formed consent for participation in the study. Control subjects were matched
with the patients (cases) for age and sex. All controls lived in the area of the
Gezira region in which S. mansoni is endemic.
b The genotype distributions for the three polymorphisms did not deviate from
Hardy-Weinberg equilibrium within the control group (
2 	 1.05, 0.03, and 0.71
for TNF- 376, 308, and 238, respectively).
c Fisher’s exact test was carried out with SPSS software to test the association
between TNF- polymorphisms and disease.
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association between these TNF- alleles conferring higher lev-
els of transcription and PPF is not consistent with the hypo-
thetical association between higher levels of TNF- production
and PPF. In conclusion, our results show that the TNF- poly-
morphisms tested here are unlikely to play an important role in
the progression of the disease from mild to severe PPF. How-
ever, our data do not exclude the possibility that these poly-
morphisms play a minor role in disease development or that
other polymorphisms (in the TNF-–HLA locus), not in link-
age disequilibrium with the polymorphisms studied here, are
associated with PPF. This hypothesis, which needs to be con-
firmed, is consistent with previous results described by Hira-
yama (26), showing that in Schistosomiasis japonica infection
(another form of hepatic schistosomiasis) the frequencies of
several HLA class II alleles were significantly increased or de-
creased in patients with or without fibrosis. The HLA-DRB1*1101-
DQB1*0301-DQA1*0501 haplotype decreases susceptibility to
grade I, II, and III fibrosis, whereas the HLA-DRB1*1501-
DRB5*0101 haplotype increases this susceptibility.
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